| US 7,566,447 B2 | ||
| Biocides | ||
| Jane Homan, Hillpoint, Wis. (US); Michael Imboden, Madison, Wis. (US); Michael Riggs, Tucson, Ariz. (US); Stephane Carryn, Brussels (Belgium); and Deborah A. Schaefer, Tuscon, Ariz. (US) | ||
| Assigned to Iogenetics, LLC, Madison, Wis. (US); and The Arizona Board of Regents on Behalf of the University of Arizona, Tucson, Ariz. (US) | ||
| Filed on Oct. 20, 2005, as Appl. No. 11/254,500. | ||
| Application 11/254500 is a continuation in part of application No. 10/844837, filed on May 13, 2004. | ||
| Claims priority of provisional application 60/470841, filed on May 15, 2003. | ||
| Claims priority of provisional application 60/620642, filed on Oct. 20, 2004. | ||
| Prior Publication US 2006/0147442 A1, Jul. 06, 2006 | ||
| Int. Cl. A61K 38/43 (2006.01); A61L 9/01 (2006.01); C07K 14/00 (2006.01); C07K 17/00 (2006.01); C07K 1/00 (2006.01); C12P 21/08 (2006.01); C07K 16/00 (2006.01); C11D 3/386 (2006.01); C12S 11/00 (2006.01) | ||
| U.S. Cl. 424—94.1 [424/76.8; 530/350; 530/388.6; 930/240; 510/305] | 5 Claims |
| 1. A method of treating a subject comprising:
a) providing
(i) a protein biocide active against Cryptosporidium parvum, wherein said protein biocide is phospholipase A2; and
(ii) a subject infected with Cryptosporidium parvum; and
b) orally administering said protein biocide to said subject under conditions such that said protein biocide reduces the growth
or replication of said Cryptosporidium parvum.
|